MEDTECH EUROPE

Their core work

MedTech Europe is the European trade association for the medical technology industry, representing manufacturers and suppliers of medical devices, in vitro diagnostics, and digital health products. Their H2020 work focuses on coordination and ecosystem-building rather than laboratory research — they convene industry actors, map technology landscapes, and drive policy alignment. In EURIPHI they led a pan-European initiative to reform how health systems procure innovation, promoting pre-commercial procurement (PCP) and public procurement of innovative solutions (PPI) as tools to pull medical technology into clinical practice. In NOBEL they contributed industry perspective to mobilising the nano-biomedical ecosystem, connecting research translation with commercial and regulatory realities.

What they specialise in

How they've shifted over time

In their first H2020 engagement (NOBEL, 2017–2020), MedTech Europe concentrated on technology ecosystem fundamentals: nanomedicine translation, open innovation pipelines, start-up engagement, and international network-building — work that maps directly to their industry association role of growing the medtech sector. By 2019, their focus shifted decisively toward procurement reform and health system transformation: EURIPHI's keywords (PPI, PCP, value-based healthcare, integrated care, rapid diagnostics, cross-border healthcare) signal a move upstream into how health systems buy and adopt innovation, not just how industry creates it. The trend is clear — from "how do we build a stronger medtech ecosystem" to "how do we get health systems to procure what that ecosystem produces."

MedTech Europe is moving toward the demand side of healthcare — health system procurement, cross-border adoption, and outcome-based evaluation — making them a valuable partner for any initiative trying to scale a health technology from development into widespread clinical use.

How they like to work

MedTech Europe has taken both the coordinator role (EURIPHI) and the partner role (NOBEL), showing flexibility depending on project mandate. Despite only two projects, they accumulated 34 unique consortium partners across 12 countries — an average of 17 partners per project — suggesting they naturally anchor large, multi-stakeholder coalitions rather than working in small focused teams. This reflects their core function as an industry association: they bring breadth and convening power, not narrow technical depth.

MedTech Europe has collaborated with 34 unique partners across 12 countries from just two projects, indicating an unusually broad reach for their project volume. Their Brussels base and pan-European industry mandate means their network spans national health ministries, hospital procurement authorities, technology companies, and research institutes across the EU.

What sets them apart

MedTech Europe is one of the few H2020 participants that brings the formal voice of an entire industry sector rather than a single institution — their outputs carry weight with regulators, procurers, and policymakers in a way that individual companies or universities cannot replicate. For consortium builders, they offer direct access to a network spanning the full medtech value chain, from SME startups to large device manufacturers, without the conflict-of-interest constraints of a single company partner. Their specialisation in procurement innovation (PPI/PCP) is particularly rare and valuable for projects aiming to link research with actual health system adoption.

Highlights from their portfolio

• EURIPHI
  MedTech Europe served as coordinator of this pan-European procurement reform initiative — their largest funded project (EUR 386,250) and a demonstration of their ability to lead complex, multi-country health system transformation work.
• NOBEL
  Participation in this nano-biomedical ecosystem project shows MedTech Europe's reach beyond pure health policy into deep technology areas, bridging nanomedicine research with industry translation and international cooperation.